Advancing Psychedelic Clinical Study Design - Virtual Public Meeting Organized by Reagan-Udall Foundation

Over the past decade, psychedelic compounds like psilocybin and ecstasy have emerged as potentially life-changing treatments for mental illnesses, including major depressive disorder and posttraumatic stress disorder. These psychedelic products may be synthetic compounds or extracts from natural products (such as magic mushroom). They usually have hallucinations effects and belongs to the substance control products. 

Academics and pharmaceutical/biotech companies are now interested in developing the psychedelic products for therapeutic uses in treating diseases like major depression, PTSD, Pakington's disease,...

In order to obtain the regulatory approval, various phases of clinical trials need to be conducted. The clinical trial designs for psychedelic drugs are more complicated than typical drugs because of its known side effects and the nature of the substance-controlled products. 

Reagan-Udall Foundation recently organized a virtual public meeting to discuss "advancing psychedelic clinical study design". During this public meeting, attendees discussed the experience of scientists working with psychedelics in FDA-authorized clinical studies and drug development, considerations for psychedelics in clinical trial designs, and perspectives and current research in psychedelic clinical trials. FDA presenters provided an overview of its newly issued guidance "Psychedelic Drugs: Considerations for Clinical Investigations."

Video recording of this virtual public meeting is available on Reagan-Udall Foundation website: 

Advancing Psychedelic Clinical Study Design
Virtual Public Meeting